



NATIONAL AND KAPODISTRIAN  
UNIVERSITY OF ATHENS  
SCHOOL OF HEALTH SCIENCES

UNIVERSITY GENERAL HOSPITAL - ATTIKON

ATTIKON



# ATHENA 2019

## International Conference

**A**PPROACHING **T**HE **S**EVERELY **I**NFECTED **P**ATIENT

19-21 NOVEMBER 2019  
DIVANI CARAVEL HOTEL - ATHENS GREECE

[www.ATHENAconference.com](http://www.ATHENAconference.com)

**F I N A L P R O G R A M**

Proud Supporter of **ATHENA 2019**  
*Approaching the severely infected patient*

## A NEW HOPE FOR SERIOUS INFECTIONS




### **Rezafungin acetate**

A novel, broad spectrum, once weekly echinocandin in Phase 3 clinical development for First-line therapy of Invasive Candidiasis and Candidemia and Prophylaxis of Invasive Fungal Infections

### **Cloudbreak® platform-Antiviral Conjugates (AVCs)**

Novel Fc conjugates with multimodal mechanism of action for the prevention and treatment of influenza and other viral diseases

<https://www.cidara.com>



Πριν τη συνταγογράφηση συμβουλευθείτε την Πλήρη Περιλήψη  
Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.



Amomed Φαρμακευτική Μ.Ε.Π.Ε  
Μιχαλακοπούλου 105 - 115 27, Αθήνα, Τηλ: 210 7781283, Fax: 210 7782831, [www.amomed.com](http://www.amomed.com)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

## SCIENTIFIC - ORGANIZING COMMITTEES

### Chair of the Conference

George Dimopoulos (*Greece*)

### International Scientific Committee

Akova Murat (*Turkey*)  
Bassetti Matteo (*Italy*)  
Calandra Thierry (*Switzerland*)  
Carmeli Yehuda (*Israel*)  
Chastre Jean (*France*)  
Cornely Oliver (*Germany*)  
Dabrowski Wojciech (*Poland*)  
De Waele Jan (*Belgium*)  
Eckmann Christian (*Germany*)  
Ghannum Mahmud (*USA*)  
Guzman Oscar (*USA*)  
Iotti Giorgio Antonio (*Italy*)  
Kollef Marin (*USA*)  
Laterre Pierre Francois (*Belgium*)  
Menichetti Francesco (*Italy*)  
Migliori Giovanni Battista (*Italy*)  
Montravers Philippe (*France*)  
Nicolau David (*USA*)  
Niederman Michael (*USA*)  
Nseir Saad (*France*)  
Paiva José-Artur (*Portugal*)  
Palmer Lucy (*USA*)  
Petrosillo Nicola (*Italy*)  
Póvoa Pedro (*Portugal*)  
Rello Jordi (*Spain*)  
Rudiger Alain (*Switzerland*)  
Sotgiu Giovanni (*Italy*)  
Timsit Jean-François (*France*)  
Van der Meer Joser (*The Netherlands*)  
Vincent Jean-Louis (*Belgium*)  
Vogelaers Dirk (*Belgium*)  
Wilcox Mark (*UK*)

### National Organizing & Scientific Committee

Antoniadou Eleni  
Armaganidis Apostolos  
Arvaniti Kostoula  
Baltopoulos George  
Daikos Georgios  
Gargalianos Panagiotis  
Georgopoulos Dimitrios  
Giamarellos Evangelos  
Giamarellou Helen  
Gogos Charalampos  
Kaprauelos Nikolaos  
Kofteridis Diamantis  
Komnos Apostolos  
Kotanidou Anastasia  
Koulendi Despoina  
Koulouras Vasileios  
Koulouris Nikolaos  
Koutelidakis Ioannis  
Koutsoukou Antonia  
Matthaiou Dimitrios  
Metallidis Symeon  
Myrianthefs Pavlos  
Orfanos Stylianos  
Paramythiotou Elisavet  
Pnevmatikos Ioannis  
Poulakou Garyphallia  
Pournaras Spiros  
Sambatakou Helen  
Theodorakopoulos George  
Theodorakopoulou Maria  
Tsangaris Iraklis  
Vassilakopoulos Theodoros  
Vlachogianni Glykeria  
Zakynthinos Epaminondas

### Secretariat

Congress World  
27, Michalakopoulou Ave., 11528 Athens, Greece  
Tel.: +30 210 7210001, +30 210 7210052, Fax: +30 210 7210051  
e-mail: reception@congressworld.gr

# ATHENA 2019

## International Conference

APPROACHING THE SEVERELY INFECTED PATIENT

19-21 NOVEMBER 2019  
DIVANI CARAVEL HOTEL, ATHENS GREECE

### Endorsed by



Hellenic Society of Intensive Care Medicine



Hellenic Society of Infectious Diseases



Hellenic Thoracic Society



Hellenic Society of Surgical Infections



Hellenic Institute for the Study of Sepsis





ΕΞΕΛΙΣΣΟΥΜΕ ΤΙΣ  
ΘΕΡΑΠΕΙΕΣ.  
ΒΕΛΤΙΩΝΟΥΜΕ  
ΤΗ ΖΩΗ.

ΓΙ' ΑΥΤΟ  
ΕΙΜΑΣΤΕ  
ΕΔΩ.

Η **Gilead Sciences** είναι μια πρωτοπόρος βιοφαρμακευτική εταιρεία που ερευνά και αναπτύσσει καινοτόμες θεραπείες σε τομείς που υπάρχουν σημαντικά θεραπευτικά κενά.

Ο πρωταρχικός σκοπός μας είναι να βοηθήσουμε τους ανθρώπους που πάσχουν από νόσους απειλητικές για τη ζωή.

Η γκάμα των προϊόντων μας περιλαμβάνει σειρά φαρμάκων πρώτης γραμμής, συμπεριλαμβανομένων ολοκληρωμένων σχημάτων ενός δισκίου για την αντιμετώπιση του ιού HIV και της χρόνιας Ηπατίτιδας C, καθώς και την πρώτη CAR-T κυτταρική θεραπεία για την αντιμετώπιση προχωρημένης νόσου για δύο τύπους επιθετικού Non-Hodgkin λεμφώματος, σε ενήλικες ασθενείς.

Χάρη στις καινοτόμες θεραπείες που έχει αναπτύξει η Gilead Sciences, εκατομμύρια άνθρωποι σε όλο τον κόσμο ζουν έχοντας καλύτερη υγεία και ποιότητα ζωής.

## WELCOME LETTER

Dear Colleagues,


On behalf of the organizing committee it is a great pleasure, to invite all of you to join ATHENA 2019 Conference which will be held on November 19-21, 2019 in Athens, Greece.

ATHENA 2019 Conference is a major international multidisciplinary event, in the field of severe infections taking place every 2 years in Athens Greece and attended nationally and internationally by upwards of 500 attendees from all over the country and worldwide. The conference has the aim to provide the opportunity for the audience to interact with world-distinguished speakers and profit from their deep knowledge and expertise in difficult aspects of the current practice on diagnosis, treatment and management of severe infections. During the last years the organizing and scientific committee has been focused to make this congress an important scientific event beyond the Greek borders, open to friendships and collaborations in order to gain worldwide warm acceptance and recognition for its scientific merit. The success of the past congress, shows us that we are on the right path towards this goal. The symposium will be held at the foot of Acropolis hill and next to the New Acropolis Museum, in an environment linked with the ancient Greek history. Delegates will also have the opportunity to feel the pulse of modern Athens, by strolling at the heart of the city through live and sophisticated neighborhoods nearby the venue. In this website you will find all the information needed concerning the implementation of the congress. The material will soon be enriched with further details for your convenience. We are confident that ATHENA 2019 will represent an unforgettable personal and professional experience, and we look forward to welcoming you in Athens.

As the chair of the organizing committee, I would like to send my warmest regards and invite all of you to a stimulating scientific event.



Best Regards,  
The Chair of the Congress  
**Professor George Dimopoulos**



**HAMILTON  
MEDICAL**  
Intelligent Ventilation since 1983

## IntelliSync+

Keeping an eye on patient-ventilator synchrony

Significant patient-ventilator asynchronies occur in more than 25% of all mechanically ventilated patients<sup>1</sup>, and are associated with increased work of breathing<sup>2</sup>, prolonged ventilation time<sup>1</sup>, and higher mortality<sup>3</sup>.

The well-trained eye of a ventilation expert is capable of detecting asynchronies by analyzing the waveform shapes of either the flow or the pressure waveforms. However, the expert cannot always be at the bedside, and the patient condition can change from breath to breath.

That is where IntelliSync+ takes over. This new technology mimics the expert's eye to identify signs of patient effort (trigger) or relaxation (cycling), thus replacing conventional trigger settings for inspiration and expiration.

1 Thille AW, Intensive Care Med. 2006 | 2 Tassaux D, Am J Respir Crit Care Med. 2005 | 3 Blanch L, Intensive Care Med. 2015

**PAPAPOSTOLOU**  
HEALTHCARE TECHNOLOGIES  
est. 1914

ΑΘΗΝΑ Εθν. Αντιστάσεως 93, 154 51, Νέο Ψυχικό Τ. +30 210 67 90 000

ΘΕΣΣΑΛΟΝΙΚΗ Πλ. Συνταγανίου 4, 546 21 Τ. +30 2310 233 251

Ε: info@papapostolou.gr www.papapostolou.gr

ΠΑΤΡΑ - ΙΩΑΝΝΙΝΑ - ΗΡΑΚΛΕΙΟ - ΣΑΛΙΝΑ - ΑΛΕΞΑΝΔΡΕΙΑ - ΚΟΖΑΝΗ

## SCIENTIFIC PROGRAM

### Tuesday 19-11-2019

09.00-09.15	<b>Welcome and Introductions</b>	<b>G. Dimopoulos</b>
09.15-11.00	<b>sCAP in the ICU</b> <i>Chairs: A. Armaganidis – A. Koutsoukou</i>	
09.15-09.30	Community healthcare associated infections: More similar to hospital-acquired?	<b>P. Pova</b>
09.30-09.45	Short course antibiotic therapy for pneumonia: Is it safe?	<b>M. Kollef</b>
09.45-10.00	VAE vs VAP: The central role of hypoxemia	<b>S. Nseir</b>
10.00-10.15	sCAP in immunocompromised patients	<b>S. Metallidis</b>
10.15-10.30	Burden and unmet needs for CAP	<b>J. Rello</b>
10.30-11.00	<i>Q &amp; A / Discussion</i>	
11.00-11.30	<b>Satellite Lecture (page 15)</b>	
11.30-12.00	<b>Satellite Lecture (page 15)</b>	
12.00-13.00	<b>Break</b>	
13.00-15.00	<b>Attractive issues on infections in the ICU</b> <i>Chairs: A. Komnos – E. Antoniadou</i>	
13.00-13.15	Prolonged infusion of antibiotics: When and how?	<b>J. De Waele</b>
13.15-13.30	Probiotics/synbiotics for ICU patients: Are they still on board?	<b>M. Akova</b>
13.30-13.45	Rapid microbiologic diagnostics - Can they make a difference in patient outcomes?	<b>M. Kollef</b>
13.45-14.00	C difficile antitoxin and prevention of infection	<b>M. Wilcox</b>
14.00-14.15	CRE in IA sepsis - How big is the problem?	<b>C. Eckmann</b>
14.15-14.30	Long acting antibiotics: The future?	<b>F. Menicchetti</b>
14.30-15.00	<i>Q &amp; A / Discussion</i>	

19-21 November 2019, Divani Caravel Hotel, ATHENS, GREECE



## SCIENTIFIC PROGRAM

### Tuesday 19-11-2019

#### 15.00-17.00 Next Generation Antibiotics

*Chairs: E. Zakynthinos – C. Gogos*

15.00-15.15	Omadocycline	Y. Carmeli
15.15-15.30	Eravacycline	D. Nicolau
15.30-15.45	Lefamulin	M. Bassetti
15.45-16.00	Meropenem-Varbobactam	E. Giamarellos
16.00-16.15	Aztreonam-Avibactam	M. Akova
16.15-16.30	Imipenem-Relebactam	J.F. Timsit
16.30-17.00	<i>Q &amp; A / Discussion</i>	

#### 17.00-17.30 Break

#### 17.30-19.00 Satellite Symposium (page 15)

#### 19.00-19.30 Award Ceremony dedicated to Prof. Helen Giamarellou

*Chair: G. Dimopoulos*

A fight of 50 years against infections H. Giamarellou

## SCIENTIFIC PROGRAM

### Wednesday 20-11-2019

#### 09.00-11.00 Lessons from the management of difficult infections in the ICU

*Chairs: J. Pnevmatikos – K. Arvaniti*

09.00-09.15	Rapid diagnosis of respiratory infections	S. Metallidis
09.15-09.30	MDR Pseudomonas infections: Aminoglycosides and colistin do not improve outcome	Y. Carmeli
09.30-09.45	Do aerolized antibiotics still have a role for VAP?	J. Rello
09.45-10.00	Should procalcitonin use be mandatory for determining antibiotic duration?	P. Pova
10.00-10.15	Minocycline and rifampin against MDR	M. Bassetti
10.15-10.30	Why immunocompromised patients fail to respond to antifungals	O. Cornely
10.30-11.00	<i>Q &amp; A / Discussion</i>	

#### 11.00-12.00 Satellite Symposium (page 15)

#### 12.00-12.30 State of the Art Lecture

*Chairs: H. Sambatakou – P. Gargalianos*

Bacteriome and mycobiome interactions: Effect of health and disease M. Ghannoum

#### 12.30-13.30 Break

#### 13.30-15.30 Towards the future

*Chairs: E. Zakynthinos – G. Vlachogianni*

13.00-13.15	e-learning in infection prevention and control	D. Vogelaers
13.15-13.30	Lasers and nanoparticles into biofilms	M. Ghannoum
13.30-13.45	The importance of viruses infections in ICU patients	J. Chastre
13.45-14.00	Sepsis: Right time for antibiotic therapy?	T. Calandra
14.00-14.15	Bacteriophages for antimicrobial therapy	J. Van der Meer
14.15-14.30	Siderophore - Antibiotic conjugates	D. Nicolau
14.30-15.00	<i>Q &amp; A / Discussion</i>	

19-21 November 2019, Divani Caravel Hotel, ATHENS, GREECE

## SCIENTIFIC PROGRAM

### Wednesday 20-11-2019

#### 15.30-17.30 Surgical infections

*Chairs: V. Koulouras – I. Koutelidakis*

15.30-15.45	Severe Acute Pancreatitis: When to use antibiotics?	J. De Waele
15.45-16.00	Necrotizing fasciitis	P. Montravers
16.00-16.15	Source control in intrabdominal sepsis - Tips and tricks for non-surgeons	C. Eckmann
16.15-16.30	<i>C. difficile</i> infections: New options for treatment	M. Wilcox
16.30-16.45	Cardiovascular implantable device infections	N. Petrosillo
16.45-17.00	Chlorhexidine for everything?	M. Niederman
17.00-17.30	<i>Q &amp; A / Discussion</i>	

#### 17.30-18.00 Break

#### 18.00-18.30 Satellite Lecture (page 16)

#### 18.30-19.30 Satellite Symposium (page 16)

#### 19.30-20.00 State of the art Lecture

*Chair: E. Giamarellos*

Modulating the microbiota in critically ill patients (antibiotics, SDD, fecal transplantation)	J. Van der Meer
------------------------------------------------------------------------------------------------------	-----------------

## SCIENTIFIC PROGRAM

### Thursday 21-11-2019

#### 09.00-11.00 Fungal infections

*Chairs: S. Orfanos – D. Kofteridis*

09.00-09.15	Fungal biofilm	M. Ghannoum
09.15-09.30	<i>Candida auris</i> : A new enemy?	T. Calandra
09.30-09.45	Echinocandins: Mechanisms of resistance	J.A. Paiva
09.45-10.00	New antifungals (APX001, F901318, AmB Cochleate, SCY078, VL2397)	O. Cornely
10.00-10.15	Rare cases of Aspergillosis (tracheobronchitis, pericardial, cerebral) in the ICU	D. Vogelaers
10.15-10.30	Rezafulgin	H. Sambatakou
10.30-11.00	<i>Q &amp; A / Discussion</i>	

#### 11.00-11.30 State of the art lecture

*Chair: T. Vassilakopoulos*

Can we apply SSC guidelines in every single ICU in the world? The view from LMIC	J.L. Vincent
-------------------------------------------------------------------------------------	--------------

#### 11.30-13.30 How to...

*Chairs: G. Baltopoulos – A. Kotanidou*

11.30-11.45	... save Carbapenems in the ICU	P. Montravers
11.45-12.00	... manage Gram positive resistant infections	J. Chastre
12.00-12.15	... treat malaria in the ICU: Challenges in management	N. Petrosillo
12.15-12.30	... optimize delivery of inhaled antibiotics in the ICU	L. Palmer
12.30-12.45	... approach influenza - associated Aspergillosis	J.A. Paiva
12.45-13.00	... treat measles outbreaks	F. Menichetti
13.00-13.30	<i>Q &amp; A / Discussion</i>	

#### 13.30-14.30 Break



---

## SCIENTIFIC PROGRAM

### Thursday 21-11-2019

#### 14.30-15.30 Tuberculosis in the ICU

*Chairs: N. Koulouris – N. Kapravelos*

14.30-14.50 New drugs against tuberculosis **G.B. Migliori**

14.50-15.10 How to treat MDR/PDR Tuberculosis **G. Sotgiu**

15.10-15.30 *Q & A / Discussion*

15.30-16.30 **Satellite Symposium** (page 17)

16.30-17.00 **Satellite Lecture** (page 17)

17.00-17.30 **Satellite Lecture** (page 17)

17.30 **Closing and Remarks of the Conference**

---

## SATELLITE SYMPOSIA & LECTURES

### Tuesday 19-11-2019

#### 11.00-11.30 **Satellite Lecture (HAMILTON MEDICAL)**

*Chair: D. Georgopoulos*

Open Lung Approach 2.0 **G.A. Iotti**

*Q & A / Discussion*

#### 11.30-12.00 **Satellite Lecture (3M)**

*Chair: D. Matthaiou*

CRBSI's prevention. Health Economics and Clinical Outcomes **G. Theodorakopoulos**

*Q & A / Discussion*

#### 17.30-19.00 **Satellite Symposium (PFIZER)**

**The role of ceftazidime/avibactam in the treatment of resistant Gram-negative infections**

*Chairs: G. Daikos – H. Giamarellou*

17.30-17.45 Mechanisms of resistance in *Pseudomonas* and *Klebsiella*:  
The role of ceftazidime avibactam **G. Daikos**

17.45-18.00 PK/PD in critically ill patients:  
Pharmacology of a  $\beta$ -lactam/  
 $\beta$ -lactamase inhibitor **D. Nicolau**

18.00-18.15 Greek experience with ceftazidime –  
avibactam **H. Giamarellou**

18.15-18.30 Worldwide experience with ceftazidime  
– avibactam **M. Bassetti**

18.30-19.00 *Q & A / Discussion*



## SATELLITE SYMPOSIA & LECTURES

### Wednesday 20-11-2019

#### 11.00-12.00 Satellite Symposium (NORMA) Nebulized antibiotics: The right position

Chair: **G. Poulakou**

11.00-11.20 How to reduce bacterial resistance using inhaled antibiotics **L. Palmer**

11.20-11.40 Nebulized colistin: When and why? **J. Rello**

11.40-12.00 *Q & A / Discussion*

#### 18.00-18.30 Satellite Lecture (PFIZER)

Chair: **A. Koutsoukou**

18.00-18.20 Treating aspergillosis in ICU: The role of isavuconazole **G. Dimopoulos**

18.20-18.30 *Q & A / Discussion*

#### 18.30-19.30 Satellite Symposium (BIOMERIEUX)

**The use of syndromic testing to improve antibiotic use in patients with severe pneumonia**

Chair: **P.F. Laterre**

18.30-18.50 Applying Molecular Syndromic Testing alongside biomarkers: the PROGRESS paradigm **E. Giamarellos**

18.50-19.10 Using syndromic testing to challenge the paradigm of antibiotic use in patients with severe pneumonia **P.F. Laterre**

19.10-19.30 *Q & A / Discussion*

## SATELLITE SYMPOSIA & LECTURES

### Thursday 21-11-2019

#### 15.30-16.30 Satellite Symposium (AMOMED) Decatecholaminization in the ICU

Chair: **P. Myrianthefts**

15.30-15.50 Catecholamine-toxicity in ICU patients and therapeutic alternatives in clinical practice **A. Rudiger**

15.50-16.10 Landiolol - A new  $\beta$ -blocker in the ICU **W. Dabrowski**

16.10-16.30 *Q & A / Discussion*

#### 16.30-17.00 Satellite Lecture (BAXTER) Fluids in the ICU

Chair: **I. Tsangaris**

16.30-16.50 Volume replacement with a new balanced crystalloid solution **P. Myrianthefts**

16.50-17.00 *Q & A / Discussion*

#### 17.00-17.30 Satellite Lecture (Helix<sup>2</sup>-T2Biosystems)

Chair: **S. Pournaras**

Impact of the T2Bacteria and T2Candida panels on changing clinical outcomes **O. Guzman**

## GENERAL INFORMATION

### CONFERENCE VENUE

The venue of the conference is the Olympia Hall, in the DIVANI CARAVEL Hotel, which is situated in the heart of Athens, close to numerous sites of interest and cultural opportunities.

### DATES

The conference will be held on November 19<sup>th</sup> – 21<sup>st</sup>, 2019.

### OFFICIAL LANGUAGE

The official language of the conference will be English. All printed material and oral presentations will be in English. No simultaneous interpretation in other languages will be provided.

### REGISTRATION FEE

The registration fee is 200€ (plus 24% VAT). Includes entry to all sessions, the exhibition area, coffee breaks during the conference and all congress materials and administration costs.

### ACCOMMODATION

Accommodation will be offered at the Divani Caravel Hotel for participants, not staying in Athens.

### INTERNET ACCESS

Wireless Internet connection is available and accessible to all participants in the Hotel's premises, without any additional charge. An internet corner will also be set in the exhibition area, including laptops, for participants' use.

### ORAL PRESENTATIONS

Speakers are kindly requested to hand in the PowerPoint file of their talk to the Conference's Technical Secretariat, at least 1 hour before their presentation time.

## SPONSORS

### PLATINUM



### GOLD



### SILVER



### BRONZE



### CONTRIBUTORS





## FACULTY LIST

- Akova Murat, M.D.**, Professor of Medicine, Hacettepe University School of Medicine, Department of Infectious Disease, Ankara, Turkey
- Antoniadou Eleni**, Pneumologist-Intensivist, Director of ICU “G. Gennimatas” General Hospital, Thessaloniki, Greece
- Armaganidis Apostolos**, Professor of Pulmonary and Intensive Care Medicine, Medical School, National and Kapodistrian University of Athens, Head of the 2nd Critical Care Department, “Attikon” University Hospital, Athens, Greece
- Arvaniti Kostoula, MD**, Intensivist, ICU, “Papageorgiou” Hospital, Thessaloniki, Greece
- Baltopoulos George, MD, PhD**, Professor Emeritus, National & Kapodistrian University of Athens, Critical Care & Pulmonary diseases
- Bassetti Matteo, MD, PhD**, Direttore Clinica Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Head Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy
- Calandra Thierry, MD, PhD**, Professor of Medicine, Head, Infectious Diseases Service, University Hospital Lausanne, Switzerland
- Carmeli Yehuda, MD, MPH**, Professor of Medicine, Tel Aviv University, Head, National Institute for Antibiotic Resistance & Infection Control, Ministry of Health
- Chastre Jean**, Consulting Professor of Medicine and Intensive care Medicine at Paris, 6th University School of Medicine, and Hôpital Pitié-Salpêtrière, Paris, France
- Cornely Oliver**, Professor of Medicine, Director, Translational Research/CECAD Institute, University of Cologne, Director, Clinical Trials Center Cologne/CTC Cologne, Professor of Internal Medicine/Department I of Internal Medicine, University Hospital of Cologne, Germany
- Dabrowsky Wojciech**, Professor, MD Medical University of Lublin, Anaesthesiology Intensive Care, Poland
- Daikos Georgios**, Associate Professor of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- De Waele Jan**, Professor, Intensivist, Ghent University Hospital, Ghent, Belgium
- Dimopoulos George, MD, PhD, FCCP, FECCM**, Professor Critical Care Medicine, Critical Care Department, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Eckmann Christian**, Professor, MD, PhD, Antibiotic Stewardship Expert ECDC/DGKH, Chief of Surgery, Department of General, Visceral and Thoracic Surgery, Klinikum Peine, Medical University Hannover, Germany
- Gargalianos Panagiotis, MD, PhD**, Internal Medicine - Infectious Diseases, Director, 1st Internal Medicine Unit, “G. Gennimatas” General Hospital, Athens, Greece

## FACULTY LIST

- Ghannum Mahmud, PHD, MBA, FAAM, FIDSA**, Professor and Director, Center for Medical Mycology and Integrated Microbiome, University Hospitals Cleveland Medical Center and Case Western Reserve University, USA
- Georgopoulos Dimitrios**, Professor of Medicine, Director of Intensive Care Medicine Department, University Hospital of Heraklion, School of Medicine, University of Crete, Herakleion, Greece
- Giamarellos Evangelos**, Professor of Internal Medicine, 4th Department of Internal Medicine, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Giamarellou Helen, MD, PhD**, Professor of Internal Medicine and Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Gogos Charalampos**, Professor and Chairman, Department of Medicine, Patras University Medical School, Patras, Greece
- Guzman Oscar**, PharmD, BCCCP, FCCM, Medical Science Liaison, USA
- Iotti Giorgio Antonio**, Professor of Anesthesiology and Intensive Care, University of Pavia, Italy
- Kapravelos Nikolaos**, Pneumologist-Intensivist, Director of 2nd ICU “G. Papanikolaou” General Hospital, Thessaloniki, Greece
- Kofteridis Diamantis**, Associate Professor of Internal Medicine and Infectious Diseases, School of Medicine, University of Crete, Herakleion, Greece
- Kollef Marin, MD**, Professor of Medicine, Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine, Washington University School of Medicine, Director, Critical Care Research, Director, Respiratory Care Services, Barnes-Jewish Hospital, St. Louis, Missouri, USA
- Komnos Apostolos, MD, PhD**, Coordinator Director, ICU, General Hospital of Larissa, Greece
- Kotanidou Anastasia, MD, PhD**, Professor of Pulmonary and Critical Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Koulouras Vasileios, MD, PhD**, Associate Professor of Intensive Care Medicine Medical School, University of Ioannina
- Koulouris Nikolaos**, Professor of Pneumology, Medical School, National and Kapodistrian University of Athens, Head of 1st Academic Department of Pneumology, Hospital for Diseases of the Chest “Sotiria”, Athens, Greece
- Koutelidakis Ioannis, MD, PhD, FACS, FEBS**, Associate Professor of Surgery, 2nd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, Greece



## FACULTY LIST

**Koutsoukou Antonia**, MD, Professor ICU, 1st Dept of Respiratory Medicine, School of Medicine, National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, Greece

**Laterre Pierre-Francois**, MD, Professor of Medicine and Head of the Medical-Surgical Intensive Care Unit, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

**Matthaïou Dimitrios**, MD, MBA, PhD, Internist - Intensivist, Research Fellow Department of Critical Care, "Attikon" University Hospital, Athens, Greece

**Menichetti Francesco**, Professor of Infectious Diseases, University of Pisa, President of GISA (Italian Group for Antimicrobial Stewardship), Director U.O.C. Infectious Diseases, Pisan University Hospital, Pisa, Italy

**Metallidis Symeon**, Associate Professor of Infectious Diseases, School of Medicine, Aristotle University of Thessaloniki, Greece

**Migliori Giovanni Battista**, MD, FRCP (London), FERS, FAPSR; Director, WHO Collaborating Centre for TB and Lung Diseases, Maugeri Institute, IRCCS Tradate, Italy, European Respiratory Society (ERS) TB Collaborating Centre, Lausanne, Switzerland

**Myrianthefts Pavlos**, MD, PhD, Professor of Pulmonary Medicine & Critical Care, School of Medicine, National and Kapodistrian University of Athens, General Hospital "Agioi Anargyroi", Kifissia, Greece

**Montravers Philippe**, MD, PhD, Paris Diderot Sorbonne Cite University, Anesthesiology and Critical Care Medicine, Bichat-Claude Bernard University Hospital, HUPNSV, AP-HP, Paris, France

**Nicolau David**, PharmD, FCCP, FIDSA, Center for Anti-Infective Research & Development, Hartford Hospital, Connecticut, USA

**Niederman Michael**, Associate Division Chief, Clinical Director, Pulmonary and Critical Care Medicine, Weil Cornell Medical Center, New York, USA; Professor of Clinical Medicine, Weill Cornell Medical College, New York, USA

**Nseir Saad**, Professor, University Hospital, Lille, France

**Orfanos Stylianos**, Professor of Critical Care and Medicine, 2nd Department of Critical Care, General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

**Paiva José-Artur**, MD, PhD, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Portugal

**Palmer Lucy**, MD, Director of the Respiratory Care Unit, Associate Professor of Medicine, Stony Brook University Medical Center, USA

## FACULTY LIST

**Petrosillo Nicola**, MD, FESCMID, Director, Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Rome, Italy

**Pneumatikos Ioannis**, Pulmonologist/Intensivist, Professor of Critical Care Medicine, Head, Department of Intensive Care Unit, University Hospital of Alexandroupolis, Greece

**Poulakou Garyphallia**, Consultant, Internal Medicine and Infectious Diseases, 4th Department of Internal Medicine, General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

**Pournaras Spiros**, MD, Professor of Clinical Microbiology, School of Medicine, National and Kapodistrian University of Athens, Director, Laboratory of Clinical Microbiology, University General Hospital "Attikon", Athens, Greece

**Póvoa Pedro**, MD, PhD, Associate Professor, NOVA Medical School, CEDOC, New University of Lisbon, Portugal; Adjunct Professor, Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, OUH Odense University Hospital, Denmark; Chair of INF Section, European Society of Intensive Care Medicine, Coordinator of the Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier, CHLO

**Rello Jordi**, Professor, Vall d'Hebron Hospital Campus, Barcelona, Spain

**Rudiger Alain**, MD, Professor of Medicine and Intensive Care Medicine, University of Zurich, Head of department of Medicine, Hospital Limmattal, Switzerland

**Sambatakou Helen**, Assistant Professor in Internal Medicine and Infectious Diseases, "Hippokraton" General Hospital of Athens, Athens, Greece

**Sotgiu Giovanni**, PhD, MD, FERS, Department of Biomedical Sciences, University of Sassari, Sassari, Italy

**Theodorakopoulos George**, RN, Scientific Affairs & Education, Regulatory Affairs, MSD-HCBG, 3M Hellas MEPE, Athens, Greece

**Timsit Jean-François**, MD, PhD, Professor, Medical and Infectious Diseases, ICU Bichat Hospital Paris Inserm, Diderot University: Team 5: Descision Sciences in Infectious Disesases (DeScID), Paris, France

**Tsangaris Iraklis**, Associate Professor, 2nd Critical Care Department, Athens National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece

**Vassilakopoulos Theodoros**, Professor, Pulmonary & Critical Care Medicine Medical School, National & Kapodistrian University of Athens, "Evangelismos" University General Hospital, Athens, Greece; Secretary General, Hellenic Thoracic Society, Athens, Greece; Adjunct Professor, McGill University, Montreal, QC, Canada



## FACULTY LIST

**Van der Meer Joser**, *Emeritus Professor of Medicine, Dept. of Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands*

**Vincent Jean-Louis**, *Professor, Department of Intensive Care, Erasme Hospital, Brussels, Belgium*

**Vlachogianni Glykeria**, *Director of ICU Department, General Hospital “Agios Dimitrios”, Thessaloniki, Greece*

**Vogelaers Dirk**, General Internal Medicine, Infectious Diseases and Psychosomatic Medicine, Ghent University Hospital; Department of Internal Medicine & Pediatrics, Ghent University, Ghent, Belgium

**Wilcox Mark**, *Professor of Medical Microbiology, Sir Edward Brotherton Chair of Bacteriology, University of Leeds; Lead on C. Difficile Infection, Public Health England; Medical Advisor to National Infection Prevention & Control Lead, NHS Improvement, Leeds, UK*

**Zakynthinos Epaminondas**, *Professor of Critical Care Medicine, University of Thessaly, Larissa, Greece*

## NOTES

## NOTES



www.demo.gr

## Global presence is our passion More than 2.000 Products Worldwide

At DEMO we value the quality of our pharmaceutical products, our healthy approach to entrepreneurship, the mutual trust we build with our partners and our ability to rapidly respond to the needs of the Global Market. Our success is based on the large scale production, attained through strategic investments, and on the rapid expansion of our product portfolio, achieved through a carefully planned and a well-managed product pipeline. These are some of the reasons why DEMO is the leading Greek exporter of own-branded generic products, with a strong presence in 85 countries.

Our active ingredient:  
Supplying quality products worldwide



900+  
employees



59%  
of the employees are  
below the age of 40



57.000m<sup>2</sup>  
facilities



4  
manufacturing plants



85+  
countries



81%  
of the company's annual  
production is exported to  
international markets



2000+  
pharmaceuticals  
worldwide



18+  
awards for the development,  
business goals and  
sustainable growth

Greek Medicines  
with Global Reach



**DEMO S.A.**  
PHARMACEUTICAL INDUSTRY



**AmBisome®**  
liposomal amphotericin B



13102917206127811

Στη φαρμακεία της παρασκευάζονται κατόπιν εντολής του ασθενούς/οικογένειάς του.

**GILEAD**  
Advancing Therapeutics.  
Improving Lives.




Τρόπος Διάρθεσης: Με περιορισμένη ιατρική συνταγή.  
Μόνο για νοσοκομειακή χρήση.  
Τιμή (ex factory): 94,16€

ΚΑΚ υπεύθυνος για τη συλλογή ΑΕ στην Ελλάδα:  
Gilead Sciences Ελλάς Μ. ΕΠΕ  
Ριζογιάνης 2 & Οράκης 167 77, Τηλ: 210 89 30 100, Fax: 210 96 18 260  
Για την πλήρη, επικαιροποιημένη Π.Χ.Π. αποστείτε  
στην εταιρεία Gilead Sciences Ελλάς Μ. ΕΠΕ

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Παρακαλείστε να αναφέρετε κάθε εγκαζόμενη/πθανολογούμενη  
ανεπιθύμητη ενέργεια απευθείας στον ΕΟΦ, σύμφωνα με το εθνικό  
σύστημα αναφοράς ανεπιθύμητων ενεργειών.

**Colistin/Norma®**  
Colistimethate sodium




Έδρα: Μενάνδρου 54, 10431 Αθήνα,  
Τηλ.: 210 52.22.282, Fax: 210 52.41.368,  
E-mail: info@normahellas.gr, www.normahellas.gr





# Xydalba™

dalbavancin



Περισσότερα από 100 χρόνια  
ασταμάτητης αναζήτησης,  
είναι μόνο η αρχή.  
Αυξάνουμε την προσπάθεια,  
μειώνοντας μόνο την απόσταση  
από το μοναδικό μας στόχο,  
τη βελτίωση της  
ανθρώπινης υγείας.

GR-MEN-ADV-01-09-2018

Βελτίωση να είναι το μέλλον του παρόντος  
Αναμενόμενο  
ΟΑΕΣ ως ανεπιθύμητο γεγονός για  
όλα τα άτομα  
Συμπεράσματα του «ΣΤΕΦΑΝΙ ΚΑΡΤΑ»

Κάθε άτομο που λαμβάνει αυτό το φάρμακο πρέπει να είναι σε θέση να αναγνωρίσει  
τα συμπτώματα ανεπιθύμητων ενεργειών και να αναζητήσει βοήθεια από το γιατρό του  
ή να επικοινωνήσει με το Κέντρο Επικοινωνίας Ασφαλείας (CEA) στο 210 6269200.  
Εάν έχετε οποιαδήποτε ερώτηση, επισκεφθείτε το [www.angelini-pharma.gr](http://www.angelini-pharma.gr) ή  
επικοινωνήστε με το ΚΕΑ στο 210 6269200. Το ΚΕΑ είναι διαθέσιμο 24 ώρες το 24ωρο.

Περισσότερες πληροφορίες διατίθενται από τον κάτοχο  
της άδειας κυκλοφορίας κατόπιν αιτήσεως  
ή περιλαμβάνονται στη συνοδευτική περιγραφή  
χαρακτηριστικών του προϊόντος, το φύλλο οδηγιών  
χρήσης και τη μονογραφία του φαρμάκου.

  
ANGELINI

Angelini Pharma Hellas A.B.E.E.  
Αχαΐας 4 & Τροιζηνίας, 145 64, Ν. Κηφισιά, Αθήνα  
Τηλ: 210 6269200, Fax: 210 8071688  
e-mail: [info@angelinipharma.gr](mailto:info@angelinipharma.gr)

 **Menarini Hellas**  
Μέριμνα για την υγεία

Menarini Hellas A.E. - Αν. Δαμβέργη 7, 104 45  
Αθήνα, Τ.: 210 8316111-13, F.: 210 8317343  
[info@menarini.gr](mailto:info@menarini.gr), [www.menarini.gr](http://www.menarini.gr)

# ZAVICEFTA™

ceftazidime and avibactam



PRIX GALIEN GREECE  
*Aθήνα 2019*

ΚΑΛΥΤΕΡΟ ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ



**Pfizer Ελλάς Α.Ε.**  
Α. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,  
Τηλ. Επικοινωνίας: 210-6785800,  
Αριθ. Γ.Ε.ΜΗ. 000242901000  
**Pfizer Ελλάς Α.Ε., Cyprus Branch**  
Λεωφόρος Αθηνών 26, 2018 Ακρωτία, Κύπρος,  
Τηλ.: 22817690

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΥΤΡΙΝΗ ΚΑΡΤΑ»

Για πλήρες συστατηγορικές πληροφορίες συμβουλευτείτε την Παράρτηρη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.